Drugs / EBV-TCR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07368634 | Jun 2025 → Jun 2027 expected | Epstein-Barr virus infection, post-transplant lymphoproliferative disease | Daihong Liu | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV-TCR-T | “This study is an investigator-initiated, exploratory, open-label, single-arm, dose-escalation clinical trial designed to evaluate the safety, tolerability, and preliminary...” NCT07368634 ↗ |
| Known as | EBV-TCR-T Cell Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07368634 ↗ |
| Action | Deplete | “enabling targeted recognition and elimination of EBV-infected cells.” NCT07368634 ↗ |
| Modality | Cell therapy | “EBV-TCR-T cell injection consists of Epstein-Barr virus-specific T cell receptor-engineered T lymphocytes manufactured from peripheral blood mononuclear cells.” NCT07368634 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT07368634 ↗ |